Drug intelligence / Profile preview

KNP-701

Development stage: Preclinical
Lead developer: Kanaph Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KNP-701 is a bispecific antibody-drug conjugate designed to target both proto-oncogene protein c-MET (c-MET) and epidermal growth factor receptor (EGFR). It acts as an EGFR antagonist and c-MET inhibitor, aiming to block signaling pathways involved in tumor growth and survival. The drug was initially developed by Kanaph Therapeutics for oncology indications. As of the latest available information, its highest global R&D status is preclinical.

Targets

MET (Mesenchymal-epithelial transition factor receptor)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on KNP-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNP-701.

Explore the full profile